Trial Profile
A study to investigate predictors of response at baseline in relapsing-remitting multiple sclerosis (RRMS) patients who had no evidence of disease activity (NEDA) while on fingolimod treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 25 Feb 2016 New trial record